Immunotherapy,
Год журнала:
2024,
Номер
16(13), С. 845 - 852
Опубликована: Июль 19, 2024
Dupilumab
has
been
approved
to
treat
a
variety
of
atopic
disorders
and
was
the
first
US
FDA-approved
medication
for
treatment
eosinophilic
esophagitis
(EoE),
initially
in
May
2022,
with
expansion
use
patients
as
young
1
year
age
weighing
at
least
15
kg
January
2024.
It
is
fully
human
monoclonal
antibody
that
inhibits
both
IL-4
IL-13
signaling,
suppressing
TH2-mediated
proinflammatory
cytokines,
chemokines
IgE
implicated
EoE
pathogenesis.
Phase
II
III
trials
have
demonstrated
histologic,
endoscopic
symptomatic
improvement
disease
activity
an
overall
favorable
safety
profile.
This
article
will
review
available
clinical
trial
data
real-world
efficacy
dupilumab
EoE.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy,
Год журнала:
2023,
Номер
43(4), С. 338 - 348
Опубликована: Фев. 25, 2023
Eosinophilic
esophagitis
(EoE)
is
an
inflammatory
condition
of
the
esophagus
that
quickly
becoming
a
more
recognized
cause
esophageal
dysfunction
and
dysphagia.
The
EoE
thought
to
be
due
response
triggered
by
exposure
dietary
or
environmental
antigens.
Symptoms
may
progressive
include
reflux,
nausea,
vomiting,
dysphagia,
reduction
in
quality
life.
Both
children
adults
affected.
Initial
treatments
for
have
focused
on
elimination
diets
potentially
identify
remove
triggers,
acid
suppression
with
proton
pump
inhibitors,
topical
delivery
orally
administered
swallowed
corticosteroids.
These
therapies
are
often
ineffective
large
proportion
patients,
leading
exploration
other
approaches
focusing
cytokines
involved
response.
Most
recently,
dupilumab,
monoclonal
antibody
targeting
IL-4
received
approval
use
patients
aged
12
years
older
EoE.
Use
dupilumab
has
seen
favorable
improvements
disease
progression
symptoms
chronic
use.
Other
IL-5,
such
as
mepolizumab,
reslizumab,
benralizumab
currently
being
studied
Therapies
key
mediators
EoE,
Siglec-8
(lirentelimab),
IL-13
(cendakimab),
sphingosine
1-phosphate
receptor
(etrasimod)
evaluated
clinical
trials.
Immunotherapy,
Год журнала:
2024,
Номер
16(13), С. 845 - 852
Опубликована: Июль 19, 2024
Dupilumab
has
been
approved
to
treat
a
variety
of
atopic
disorders
and
was
the
first
US
FDA-approved
medication
for
treatment
eosinophilic
esophagitis
(EoE),
initially
in
May
2022,
with
expansion
use
patients
as
young
1
year
age
weighing
at
least
15
kg
January
2024.
It
is
fully
human
monoclonal
antibody
that
inhibits
both
IL-4
IL-13
signaling,
suppressing
TH2-mediated
proinflammatory
cytokines,
chemokines
IgE
implicated
EoE
pathogenesis.
Phase
II
III
trials
have
demonstrated
histologic,
endoscopic
symptomatic
improvement
disease
activity
an
overall
favorable
safety
profile.
This
article
will
review
available
clinical
trial
data
real-world
efficacy
dupilumab
EoE.
